{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rodriguez-Guilarte L"],"funding":["NCIPC CDC HHS"],"pagination":["407"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12796199"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["Annual vaccination is an effective strategy for preventing severe disease caused by seasonal influenza. Quadrivalent influenza vaccines (QIVs) protect against two strains of influenza A and two strains of influenza B, thereby enhancing the host antiviral neutralizing antibody response and inducing CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses. Here, we report findings from a randomized, double-blind, active-controlled phase 3 clinical trial (NCT05431725) that includes 334 healthy adults aged 18-64 years and evaluates the humoral and cellular antiviral immune responses induced by two inactivated QIVs, Sinovac-QIV and Vaxigrip-Tetra™. The primary endpoint of the study is the specific antibody responses measured by hemagglutination inhibition (HAI) assays 28 days post-vaccination, whil"],"journal":["Nature communications"],"pubmed_title":["Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial."],"pmcid":["PMC12796199"],"funding_grant_id":["U17 CE002021"],"pubmed_authors":["Rios M","Palacios PA","Bascur F","Castejon A","Rodriguez-Guilarte L","Aljaro S","Cabrera A","Alvarez-Figueroa MJ","Del Rio C","Villarroel M","Roman F","Gonzalez PA","Feijoo RM","Grandon S","Twele L","Perez CM","Perez L","Fernandez Vasquez PE","Gutierrez-Vera C","Reyes A","Jara P","Calvo M","Bueno SM","Xin Q","Rojas A","Gonzalez-Aramundiz JV","Oyonarte M","Schilling A","Angelica Dominguez M","Moreno-Tapia D","Beltran Campos D","Tovar De Sousa C","Yang W","Kalergis AM","Mendez C","Penaloza HF","Rivera DB","Carreno LJ","Astudillo P"],"additional_accession":[]},"is_claimable":false,"name":"Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.","description":"Annual vaccination is an effective strategy for preventing severe disease caused by seasonal influenza. Quadrivalent influenza vaccines (QIVs) protect against two strains of influenza A and two strains of influenza B, thereby enhancing the host antiviral neutralizing antibody response and inducing CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses. Here, we report findings from a randomized, double-blind, active-controlled phase 3 clinical trial (NCT05431725) that includes 334 healthy adults aged 18-64 years and evaluates the humoral and cellular antiviral immune responses induced by two inactivated QIVs, Sinovac-QIV and Vaxigrip-Tetra™. The primary endpoint of the study is the specific antibody responses measured by hemagglutination inhibition (HAI) assays 28 days post-vaccination, whil","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T12:24:35.297Z","creation":"2026-07-04T03:13:27.474Z"},"accession":"S-EPMC12796199","cross_references":{"pubmed":["41354738"],"doi":["10.1038/s41467-025-67102-y"]}}